Skip to main content
Erschienen in: International Journal of Clinical Oncology 1/2017

07.09.2016 | Original Article

Clinical outcomes of IMRT planned with or without PET/CT simulation for patients with pharyngeal cancers

verfasst von: Tomohiro Matsuura, Yasumasa Nishimura, Kiyoshi Nakamatsu, Shuichi Kanamori, Kazuki Ishikawa, Izumi Tachibana, Makoto Hosono, Toru Shibata

Erschienen in: International Journal of Clinical Oncology | Ausgabe 1/2017

Einloggen, um Zugang zu erhalten

Abstract

Background

Clinical results of computed tomography (CT) simulations and [18F]-fluoro-2-deoxyglucose (FDG) positron emission tomography (PET)/CT simulations were compared retrospectively.

Materials and methods

Between 2006 and 2011, [18F]-FDG PET/CT simulation was performed on 68 consecutive patients with pharyngeal cancers (PET/CT group). As an historical control, conventional CT simulation was performed on 56 consecutive patients with pharyngeal cancer between 2000 and 2006 (CT group). In the PET/CT group, the primary sites were nasopharynx (NPC), oropharynx (OPC), and hypopharynx (HPC) in 35, 20, and 13 patients, respectively; in the CT group, the primary sites were NPC, OPC, and HPC in 21, 17, and 18 patients, respectively. All but five patients in the PET/CT group were treated with intensity modulated radiation therapy (IMRT).

Results

In the PET/CT group, TNM and clinical stages changed in 11 (16 %) and eight (12 %) patients, respectively. Although the 5-year overall survival (OS) rates for the PET/CT and the CT groups were 80 and 64 %, respectively (p = 0.0420), this result may be attributable to the background difference between the two groups. Similarly, the 5-year locoregional control rates of the two groups were 82 and 70 %, respectively (p = 0.0501). Notably, marginal recurrences around the planning target volume (PTV) were only noted in four CT group patients.

Conclusion

PET/CT simulation was useful for delineating an accurate clinical target volume (CTV) of pharyngeal cancer, and its clinical results were satisfactory.
Literatur
1.
Zurück zum Zitat Schoenfeld GO, Amdur RJ, Morris CG et al (2008) Patterns of failure and toxicity after intensity-modulated radiotherapy for head and neck cancer. Int J Radiat Oncol Biol Phys 71:377–385CrossRefPubMed Schoenfeld GO, Amdur RJ, Morris CG et al (2008) Patterns of failure and toxicity after intensity-modulated radiotherapy for head and neck cancer. Int J Radiat Oncol Biol Phys 71:377–385CrossRefPubMed
2.
Zurück zum Zitat Eisbruch A, Marsh LH, Dawson LA et al (2004) Recurrences near base of skull after IMRT for head-and-neck cancer: implications for target delineation in high neck and for parotid gland sparing. Int J Radiat Oncol Biol Phys 59:28–42CrossRefPubMed Eisbruch A, Marsh LH, Dawson LA et al (2004) Recurrences near base of skull after IMRT for head-and-neck cancer: implications for target delineation in high neck and for parotid gland sparing. Int J Radiat Oncol Biol Phys 59:28–42CrossRefPubMed
3.
Zurück zum Zitat Chao KS, Ozyigit G, Tran BN et al (2003) Patterns of failure in patients receiving definitive and postoperative IMRT for head-and-neck cancer. Int J Radiat Oncol Biol Phys 55:312–321CrossRefPubMed Chao KS, Ozyigit G, Tran BN et al (2003) Patterns of failure in patients receiving definitive and postoperative IMRT for head-and-neck cancer. Int J Radiat Oncol Biol Phys 55:312–321CrossRefPubMed
4.
Zurück zum Zitat Raktoe SA, Dehnad H, Raaijmakers CP et al (2013) Origin of Tumor recurrence after intensity modulated radiation therapy for oropharyngeal squamous cell carcinoma. Int J Radiat Oncol Biol Phys 85:136–141CrossRefPubMed Raktoe SA, Dehnad H, Raaijmakers CP et al (2013) Origin of Tumor recurrence after intensity modulated radiation therapy for oropharyngeal squamous cell carcinoma. Int J Radiat Oncol Biol Phys 85:136–141CrossRefPubMed
5.
Zurück zum Zitat Nishimura Y, Shibata T, Nakamatsu K et al (2010) A two-step intensity-modulated radiation therapy method for nasopharyngeal cancer: the Kinki University experience. Jpn J Clin Oncol 40:130–138CrossRefPubMed Nishimura Y, Shibata T, Nakamatsu K et al (2010) A two-step intensity-modulated radiation therapy method for nasopharyngeal cancer: the Kinki University experience. Jpn J Clin Oncol 40:130–138CrossRefPubMed
6.
Zurück zum Zitat Rohde M, Dyrvig AK, Johansen J et al (2014) 18F-fluoro-deoxy-glucose-positron emission tomography/computed tomography in diagnosis of head and neck squamous cell carcinoma: a systematic review and meta-analysis. Eur J Cancer 50:2271–2279CrossRefPubMed Rohde M, Dyrvig AK, Johansen J et al (2014) 18F-fluoro-deoxy-glucose-positron emission tomography/computed tomography in diagnosis of head and neck squamous cell carcinoma: a systematic review and meta-analysis. Eur J Cancer 50:2271–2279CrossRefPubMed
7.
Zurück zum Zitat Xu G, Li J, Zuo X et al (2012) Comparison of whole body positron emission tomography (PET)/PET-computed tomography and conventional anatomic imaging for detecting distant malignancies in patients with head and neck cancer: a meta-analysis. Laryngoscope 122:1974–1978CrossRefPubMed Xu G, Li J, Zuo X et al (2012) Comparison of whole body positron emission tomography (PET)/PET-computed tomography and conventional anatomic imaging for detecting distant malignancies in patients with head and neck cancer: a meta-analysis. Laryngoscope 122:1974–1978CrossRefPubMed
8.
Zurück zum Zitat Deantonio L, Beldì D, Gambaro G et al (2008) FDG-PET/CT imaging for staging and radiotherapy treatment planning of head and neck carcinoma. Radiat Oncol 3:18–29CrossRef Deantonio L, Beldì D, Gambaro G et al (2008) FDG-PET/CT imaging for staging and radiotherapy treatment planning of head and neck carcinoma. Radiat Oncol 3:18–29CrossRef
9.
Zurück zum Zitat Kao CH, Hsieh TC, Yu CY et al (2010) 18F-FDG PET/CT-based gross tumor volume definition for radiotherapy in head and neck cancer: a correlation study between suitable uptake value threshold and tumor parameters. Radiat Oncol 5:2–76CrossRef Kao CH, Hsieh TC, Yu CY et al (2010) 18F-FDG PET/CT-based gross tumor volume definition for radiotherapy in head and neck cancer: a correlation study between suitable uptake value threshold and tumor parameters. Radiat Oncol 5:2–76CrossRef
10.
Zurück zum Zitat Wang D, Schultz CJ, Jursinic PA et al (2006) Initial experience of FDG-PET/CT guided IMRT of head-and-neck carcinoma. Int J Radiat Oncol Biol Phys 65:143–151CrossRefPubMed Wang D, Schultz CJ, Jursinic PA et al (2006) Initial experience of FDG-PET/CT guided IMRT of head-and-neck carcinoma. Int J Radiat Oncol Biol Phys 65:143–151CrossRefPubMed
11.
Zurück zum Zitat Schwartz DL, Ford EC, Rajendran J et al (2005) FDG-PET/CT-guided intensity modulated head and neck radiotherapy: a pilot investigation. Head Neck 27:478–487CrossRefPubMed Schwartz DL, Ford EC, Rajendran J et al (2005) FDG-PET/CT-guided intensity modulated head and neck radiotherapy: a pilot investigation. Head Neck 27:478–487CrossRefPubMed
12.
Zurück zum Zitat Vernon MR, Maheshwari M, Schultz CJ et al (2008) Clinical outcomes of patterns receiving integrated PET/CT-guided radiotherapy for head and neck carcinoma. Int J Radiat Oncol Biol Phys 70:678–684CrossRefPubMed Vernon MR, Maheshwari M, Schultz CJ et al (2008) Clinical outcomes of patterns receiving integrated PET/CT-guided radiotherapy for head and neck carcinoma. Int J Radiat Oncol Biol Phys 70:678–684CrossRefPubMed
13.
Zurück zum Zitat Eisbruch A, Foote RL, O’Sullivan B et al (2002) Intensity-modulated radiation therapy for head and neck cancer: emphasis on the selection and delineation of the targets. Semin Radiat Oncol 12:238–249CrossRefPubMed Eisbruch A, Foote RL, O’Sullivan B et al (2002) Intensity-modulated radiation therapy for head and neck cancer: emphasis on the selection and delineation of the targets. Semin Radiat Oncol 12:238–249CrossRefPubMed
14.
Zurück zum Zitat Okubo M, Nishimura Y, Nakamatsu K et al (2010) Radiation treatment planning using positron emission and computed tomography for lung and pharyngeal cancer: a multiple-threshold method for [18F] fluoro-2-deoxyglucose activity. Int J Radiat Oncol Biol Phys 77:350–356CrossRefPubMed Okubo M, Nishimura Y, Nakamatsu K et al (2010) Radiation treatment planning using positron emission and computed tomography for lung and pharyngeal cancer: a multiple-threshold method for [18F] fluoro-2-deoxyglucose activity. Int J Radiat Oncol Biol Phys 77:350–356CrossRefPubMed
15.
Zurück zum Zitat Okubo M, Nishimura Y, Nakamatsu K et al (2008) Static and moving phantom studies for radiation treatment planning in a positron emission tomography and computed tomography (PET/CT) system. Ann Nucl Med 22:579–586CrossRefPubMed Okubo M, Nishimura Y, Nakamatsu K et al (2008) Static and moving phantom studies for radiation treatment planning in a positron emission tomography and computed tomography (PET/CT) system. Ann Nucl Med 22:579–586CrossRefPubMed
16.
Zurück zum Zitat Tang L, Li L, Mao Y et al (2008) Retropharyngeal lymph node metastasis in nasopharyngeal carcinoma detected by magnetic resonance imaging. Cancer 113:347–354CrossRefPubMed Tang L, Li L, Mao Y et al (2008) Retropharyngeal lymph node metastasis in nasopharyngeal carcinoma detected by magnetic resonance imaging. Cancer 113:347–354CrossRefPubMed
17.
Zurück zum Zitat Zheng XK, Chen LH, Wang QS et al (2007) Influence of FDG-PET on computed tomography-based radiotherapy planning for locally recurrent nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 69:1381–1388CrossRefPubMed Zheng XK, Chen LH, Wang QS et al (2007) Influence of FDG-PET on computed tomography-based radiotherapy planning for locally recurrent nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 69:1381–1388CrossRefPubMed
18.
Zurück zum Zitat Hickeson M, Yun M, Matthies A et al (2002) Use of a corrected standardized uptake value based on the lesion size on CT permits accurate characterization of lung nodules on FDG-PET. Eur J Nucl Med Mol Imaging 29:1639–1647CrossRefPubMed Hickeson M, Yun M, Matthies A et al (2002) Use of a corrected standardized uptake value based on the lesion size on CT permits accurate characterization of lung nodules on FDG-PET. Eur J Nucl Med Mol Imaging 29:1639–1647CrossRefPubMed
19.
Zurück zum Zitat Paulino AC, Johnstone PA (2004) FDG-PET in radiotherapy treatment planning: pandora’s box? Int J Radiat Oncol Biol Phys 59:4–5CrossRefPubMed Paulino AC, Johnstone PA (2004) FDG-PET in radiotherapy treatment planning: pandora’s box? Int J Radiat Oncol Biol Phys 59:4–5CrossRefPubMed
20.
Zurück zum Zitat Fukui MB, Blodgett TM, Snyderman CH et al (2005) Combined PET-CT in the head and neck: part 2. Diagnostic uses and pitfalls of oncologic imaging. Radiographics 25:913–930CrossRefPubMed Fukui MB, Blodgett TM, Snyderman CH et al (2005) Combined PET-CT in the head and neck: part 2. Diagnostic uses and pitfalls of oncologic imaging. Radiographics 25:913–930CrossRefPubMed
21.
Zurück zum Zitat Vorwerk H, Hess CF (2011) Guidelines for delineation of lymphatic clinical target volumes for high conformal radiotherapy: head and neck region. Radiat Oncol 6:19–97CrossRef Vorwerk H, Hess CF (2011) Guidelines for delineation of lymphatic clinical target volumes for high conformal radiotherapy: head and neck region. Radiat Oncol 6:19–97CrossRef
22.
Zurück zum Zitat Suzuki M, Nishimura Y, Nakamatsu K et al (2006) Analysis of interfractional set-up errors and intrafractional organ motions during IMRT for head and neck tumors to define an appropriate planning target volume (PTV)- and planning organs at risk volume (PRV)-margins. Radiother Oncol 78:283–290CrossRefPubMed Suzuki M, Nishimura Y, Nakamatsu K et al (2006) Analysis of interfractional set-up errors and intrafractional organ motions during IMRT for head and neck tumors to define an appropriate planning target volume (PTV)- and planning organs at risk volume (PRV)-margins. Radiother Oncol 78:283–290CrossRefPubMed
Metadaten
Titel
Clinical outcomes of IMRT planned with or without PET/CT simulation for patients with pharyngeal cancers
verfasst von
Tomohiro Matsuura
Yasumasa Nishimura
Kiyoshi Nakamatsu
Shuichi Kanamori
Kazuki Ishikawa
Izumi Tachibana
Makoto Hosono
Toru Shibata
Publikationsdatum
07.09.2016
Verlag
Springer Japan
Erschienen in
International Journal of Clinical Oncology / Ausgabe 1/2017
Print ISSN: 1341-9625
Elektronische ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-016-1034-5

Weitere Artikel der Ausgabe 1/2017

International Journal of Clinical Oncology 1/2017 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.